Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. The Company's subsidiary, Harvest Medicine provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by okgonowon Apr 18, 2024 3:56pm
50 Views
Post# 35996677

RE:A possibility, the ANDA and 505(b)2 could BOTH be CBD

RE:A possibility, the ANDA and 505(b)2 could BOTH be CBD
subaru1i wrote: based, could both or just one (generic epidiolex) utilize SEDDS technology and be applied as two different drugs in two different areas of health care.   The logic for my thought is the single submission for CBD made by LABS to the FDA with regards to the DMF (drug master file). 

IF they are both CBD or even if 1 of them is, the good news for LABS shareholders is that it is NOT dependent on DEA rescheduling cannabis from 1 to 3.

If we look at the logic LABS followed (CEO of LABS being former CEO of Purdue Pharma Canada), and that logic being doing a CBD DMF to the FDA along with ANDA and 505(b)2,  imho, a strategy by the CEO of LABS that is not road blocked by the DEA what so ever. 

I think those that give this some thought may see as the 'path of least resistance' and can only be thankful our CEO is from the pharmaceutical industry to lead us. 




based, could both or just one (generic epidiolex) utilize SEDDS technology and be applied as two different drugs in two different areas of health care.   The logic for my thought is the single submission for CBD made by LABS to the FDA with regards to the DMF (drug master file). 

IF they are both CBD or even if 1 of them is, the good news for LABS shareholders is that it is NOT dependent on DEA rescheduling cannabis from 1 to 3.

If we look at the logic LABS followed (CEO of LABS being former CEO of Purdue Pharma Canada), and that logic being doing a CBD DMF to the FDA along with ANDA and 505(b)2,  imho, a strategy by the CEO of LABS that is not road blocked by the DEA what so ever. 

I think those that give this some thought may see as the 'path of least resistance' and can only be thankful our CEO is from the pharmaceutical industry to lead us. 


Wouldnt that be the absolute crazyiest thing to happen, the guy in charge of the Canadian Perdue,now
 in charge of a company that may be part of a drug that may be able to help all those people hooked on the stuff.

Perdue, and the infamous Sackler familie made billions off of pushing the Oxycontin getting people hooked.

you wouldent beleve it if it was in a movie  



<< Previous
Bullboard Posts
Next >>